LRP2, commonly called megalin, is a giant multiligand endocytic receptor of the LDL receptor family with high physiological relevance at epithelial interfaces, including the choroid plexus and brain barriers.[1][2] In neurodegeneration, megalin is important because it can influence macromolecule trafficking between blood, cerebrospinal fluid (CSF), and brain parenchyma, thereby shaping exposure to ligands involved in amyloid homeostasis, lipid transport, endocrine signaling, and inflammatory tone.[3][4]
Unlike single-target enzymes, LRP2 is a systems regulator: it controls uptake of many classes of ligands, and this broad cargo profile means disease effects are often indirect and context-dependent.[1:1][5] Its relevance to disorders such as Alzheimer's disease and related proteinopathies is strongest at the level of barrier biology, CSF exchange, and clearance efficiency.[3:1][4:1]
Recent structural studies have clarified LRP2 as a modular "molecular machine" for receptor-mediated endocytosis, with repeated ligand-binding modules that permit broad cargo recognition and efficient internalization cycles.[6][7]
Core functional features include:
Because LRP2 functions in tissues with high transport demand, small changes in receptor abundance or compartmental routing can produce measurable downstream effects on CSF composition and neuronal exposure to circulating signals.[3:2][8]
At the blood-CSF barrier, transporter expression is dynamic across aging and disease states.[3:3] Multiple studies indicate that receptor systems at this interface contribute to amyloid-beta movement and clearance from CSF.[4:2][9] While LRP1 has clearer direct experimental support in specific amyloid-beta transport assays, LRP2/megalin is repeatedly implicated as part of the broader clearance architecture and barrier response network.[3:4][8:1][9:1]
For translational framing:
This aligns LRP2 with endolysosomal trafficking defects and other clearance-pathway nodes rather than isolated target-centric models.[1:2][5:1]
Beyond epithelial surfaces, LRP2 expression/function has been examined in CNS-resident cells including astrocytes and microglia.[10] These data suggest that megalin may contribute to local ligand uptake programs that influence inflammatory signaling and metabolic support, although disease-stage and cell-state effects remain underdefined.
Additional brain-relevant work links LRP2 receptor systems to micronutrient and selenium-associated pathways through barrier transport networks, with potential implications for oxidative stress resilience and neuronal survival programs.[11]
Evidence is strongest at the mechanistic level (barrier transport and clearance pathways) and weaker at direct intervention-level proof. CSF studies report altered soluble megalin in AD cohorts, consistent with barrier pathway disturbance, but causality and directionality are unresolved.[8:2]
Direct human disease datasets are limited. However, because barrier and glymphatic/CSF exchange dysfunction are transdiagnostic features across neurodegenerative disorders, LRP2 is mechanistically relevant as a candidate modifier in PSP, CBD, and Parkinson's disease models that emphasize clearance failure.[3:5][10:1]
Near-term high-value directions:
These approaches are preferable to single-pathway attribution and better reflect the distributed nature of clearance biology in neurodegeneration.[1:3][3:6][5:2]
May P, Rohlmann A, Bock HH, Herz J. The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions. Annals of Medicine. 2002. ↩︎ ↩︎ ↩︎ ↩︎
Christensen EI, Birn H. Megalin and cubilin: multifunctional endocytic receptors. Nature Reviews Molecular Cell Biology. 2002. ↩︎
Krzyzanowska A, Carro E. Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent. Fluids and Barriers of the CNS. 2011. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Fujiyoshi M, Tachikawa M, Ohtsuki S, et al. Amyloid-beta peptide(1-40) elimination from cerebrospinal fluid involves low-density lipoprotein receptor-related protein 1 at the blood-cerebrospinal fluid barrier. Journal of Neurochemistry. 2011. ↩︎ ↩︎ ↩︎
Kur E, Christ A, Herz J. Endocytic receptor megalin and neurodevelopmental signaling pathways. Experimental Neurology. 2012. ↩︎ ↩︎ ↩︎
Elkhattouti A, Tella SH, et al. Structures of LRP2 reveal a molecular machine for endocytosis. Cell. 2023. ↩︎
Elkhattouti A, Tella SH, et al. Cryo-EM structures elucidate the multiligand receptor nature of megalin. PNAS. 2024. ↩︎
Dietrich M, et al. Soluble megalin is reduced in cerebrospinal fluid samples of Alzheimer's disease patients. Frontiers in Cellular Neuroscience. 2015. ↩︎ ↩︎ ↩︎
Shibata M, Yamada S, et al. Clearance of Alzheimer's amyloid-beta(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. Journal of Clinical Investigation. 2000. ↩︎ ↩︎
Muresan V, Muresan Z. Low Density Lipoprotein Receptor-related Protein 2 Expression and Function in Cultured Astrocytes and Microglia. Neurochemical Research. 2024. ↩︎ ↩︎
Burk RF, Hill KE, et al. Selenoprotein P and apolipoprotein E receptor-2 interact at the blood-brain barrier and also within the brain to maintain an essential selenium pool that protects against neurodegeneration. FASEB Journal. 2014. ↩︎